Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2

Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell–related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD) or are in advanced...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurol Neuroimmunol Neuroinflamm
Asıl Yazarlar: Graf, Jonas, Mares, Jan, Barnett, Michael, Aktas, Orhan, Albrecht, Philipp, Zamvil, Scott S., Hartung, Hans-Peter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2020
Konular:
Views & Reviews
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8063618/
https://ncbi.nlm.nih.gov/pubmed/33411674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000919
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller